A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Slides:

Advertisements

Similar presentations

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Advertisements

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

My Approach to the Patient With Familial Hypercholesterolemia

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred Rossella Spina,

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Disposition of Patients in the Atherogenic Dyslipidemia Study

Rhanderson Cardoso, MD, Roger S

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki Drogari, MD, PhD, MSc (Biochem), MSc (Nutr) Journal of Clinical Lipidology Volume 10, Issue 5, Pages 1153-1162.e3 (September 2016) DOI: 10.1016/j.jacl.2016.05.010 Copyright © 2016 National Lipid Association Terms and Conditions

Figure 1 Patient disposition. AE, adverse event; LDL-C, low-density lipoprotein cholesterol; TS, Tanner stage. *LDL-C <2.59 mmol/L (100 mg/dL). Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 2 (A) Mean unweighted, weighted, and maximum doses of atorvastatin received by children and adolescents with HeFH stratified by TS and age. (B) The percentage of subjects receiving atorvastatin 5, 10, 20, 40, or 80 mg as their maximum dose, all subjects, by TS and age. HeFH, heterozygous familial hypercholesterolemia; SE, standard error; TS, Tanner stage. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 3 Mean percentage change from baseline in LDL-C in all subjects with HeFH and by TS 1 and ≥2 and aged <10 and ≥10 years at baseline. HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; TS, Tanner stage. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 4 Percentage of subjects aged <10 years or ≥10 years at baseline achieving LDL-C goal of <3.35 mmol/L (<130 mg/dL) at each study visit. LDL-C, low-density lipoprotein cholesterol. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 5 Mean percentage change from baseline in lipid parameters at month 36/early termination in all subjects with HeFH and by TS 1 and ≥2 at baseline. Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; TC, total cholesterol; TG, triglyceride; TS, Tanner stage. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 6 Changes in the percentage of subjects in each TS over 36 months/early termination among children and adolescents with HeFH receiving atorvastatin therapy. HeFH, heterozygous familial hypercholesterolemia; TS, Tanner stage. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions

Supplemental Figure 1 Mean FMD in a subset of subjects over 36 months among children and adolescents with HeFH receiving atorvastatin therapy. FMD, flow-mediated dilation; HeFH, heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology 2016 10, 1153-1162.e3DOI: (10.1016/j.jacl.2016.05.010) Copyright © 2016 National Lipid Association Terms and Conditions